Watching safety of durvalumab with or without olaparib in endometrial cancer patients
Studies durvalumab, alone or with olaparib, in endometrial cancer patients receiving routine care.
Key facts
- Who runs it
- AstraZeneca
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 19 Sept 2025
- Expected to end
- 29 Jun 2029
- Type of study
- Observational
- Record updated
- 2 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people in Korea with endometrial cancer who are prescribed Durvalumab, with or without Olaparib, under its approved use. It watches safety and effectiveness in routine care.
- Sex
- All sexes can join.
- Disease stage
- Endometrial cancer treated under the approved use of the study drug in Korea.
Main reasons for not taking part
- Taking part in another interventional trial during the study drug treatment
- Use of the study drug for an off-label indication, not in the approved label in Korea
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients eligible for the study drug according to the approved label in Korea
- Provision of a signed and dated written informed consent by the patient or their legally acceptable representative
Who cannot take part
- Participation in any concurrent interventional trials during the period of the study drug treatment
- Other off-label indications according to the approved label in Korea
Where in South Korea
- SeoulHospital not named in the registryTaking people
About the trial
What the trial wants to find out
Objectives of this study are to assess the safety and effectiveness of Durvalumab with or without Olaparib (hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug under the approved indication in Korea.
Read full original descriptionShow less
This is a multicenter, prospective, observational, real world treatment study. Patients treated as part of routine practice at Korean healthcare centers by investigators will be identified and considered for inclusion in the study. The period of this study is expected to run for 4 years from the approval date of the indication for this study. Approximately 50 patients are expected to be enrolled during the study.
Patient will be followed for approximately 12 months from the first dose or up to 90 days after treatment discontinuation if the study drug is administered for less than 12 months, unless they withdraw consent, are lost to follow-up or death.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
- Plain-language title
- Watching safety of durvalumab with or without olaparib in endometrial cancer patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 September 2026